Aims & Scope
Current Pharmacogenomics and Personalized Medicine (CPPM) is a transdisciplinary peer-reviewed biomedical journal that reports new findings and cutting-edge concepts in both pharmacogenomics and personalized medicine under a single cover. CPPM is an accelerator for global personalized medicine and pharmacogenomics. Importantly, the journal provides a multi-disciplinary integrated platform from cell to society to address diagnostics and responsible pharmacogenomics applications in developing countries.
CPPM cooperates with the Ibero-American Network of Pharmacogenetics and the Pacific Rim Association for Clinical Pharmacogenetics and welcomes peer reviewed contributions from qualified authors in any global region including the Central and Latin American countries, Asia-Pacific and developing countries.
The Journal scope is defined by three inter-connected aims. First, we are interested in genomics/postgenomics biotechnologies and diagnostics that enable global personalized medicine science (including and beyond pharmacogenomics) as long as they explain person-to-person and population differences in disease susceptibility or response to a health intervention, and they can be mechanistically substantiated. Second, we approach personalized medicine as ‘personalized health interventions’ focusing primarily on drug therapy, but also other interventions such as nutrition, vaccines, surgical devices, emerging cell-based therapies that collectively contribute to healthcare. Third, we strive to integrate molecular and clinical investigation with public policy, global health diplomacy and social studies of biotechnology that collectively shape postgenomics future(s) and innovation trajectories in life sciences. Priority will be given to expert reviews and research articles that include original ideas and findings related to the journal scope and mandate.
This journal follows the International Committee of Medical Journal Editors (ICMJE) (www.icmje.org) guidance for authorship, peer review and editorial independence. All manuscripts submitted for publication will be immediately subjected to editorial scrutiny. Manuscripts that do not conform to the CPPM format and editorial style will be returned to the authors. Only those articles that may potentially pass the rigorous standards of the peer review process are sent out for critical appraisal by independent expert referees invited from the international editorial board and the broader scientific community.
CPPM offers a transdisciplinary, peer-reviewed and intellectually stimulating forum for academic researchers, health professionals, pharmaceutical and biotechnology industries, policy makers, government and global health stakeholders interested in pharmacogenomics and global personalized medicine. The journal is published four times per year and printed on acid-free paper.
BIOSIS Previews, BIOSIS Reviews Reports and Meetings, Scopus, EMBASE/Excerpta Medica, Chemical Abstracts, ProQuest, EMBiology, Genamics JournalSeek, Cabell's Directory, Media Finder®-Standard Periodical Directory, PubsHub, J-Gate, CNKI Scholar, Suweco CZ, EBSCO and Dimensions.
Current Pharmacogenomics was launched in 2003 and later renamed in 2008 as Current Pharmacogenomics and Personalized Medicine.
Allele Frequency Distributions of the Drug Metabolizer Genes CYP2C9*2, CYP2C9*3, and CYP2C19*17 in the Buginese Population of Indonesia, 2014: 12(4); 236 - 239
Zullies Ikawati, Theresia D. Askitosari, Lukman Hakim, Joseph Tucci and John Mitchell.
"Current Pharmacogenomics and Personalized Medicine provides access to the most recent progress and opinion in this rapidly developing field and is an indispensable source of information for scientists and clinicians who want to keep in touch with the expanding interdisciplinary advancements."
Professor of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR.